Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Cardiac Arrhythmia

Cardiac Arrhythmia

Cardiac arrhythmia refers to an abnormal heart rhythm, characterized by irregularities in the electrical activity of the heart.
This condition can manifest in various forms, including atrial fibrillation, ventricular tachycardia, and bradycardia, among others.
Cardiac arrhythmias can have serious implications, potentially leading to reduced blood flow, heart failure, and even sudden cardiac death if left untreated.
Understanding and effectively managing cardiac arrhythmias is crucial for maintaining cardiovascular health.
PubCompare.ai offers a powerful tool to optimize cardiac arrhythmia research, enabling users to easily locate relevant protocols from literature, preprints, and patents, while leveraging AI-driven comparisons to identify the best protocols and products.
This innovative tool enhances reproducibility and accuracy in cardiac arrhythmia studies, allowing researchers to experience the future of research today and advance the field of cardiovascular medicine.

Most cited protocols related to «Cardiac Arrhythmia»

1
Improved Myocardial Infarction Modeling
Experiments were carried out according to National Institutes of Health Guidelines on the Use of Laboratory Animals and all procedures were approved by the Thomas Jefferson University Committee on Animal Care. A total of 497 (384 mice for MI and 113 for I/R) male 8-10 week old C57/B6 mice were used for this study. For the MI model, mice were subjected to permanent coronary artery ligation using either the new (N) method or the classical (C) method. Mice were randomly assigned to four groups: new method of MI (MI-N) or sham (S-N); classical method of MI (MI-C) or sham (S-C). There were 119 mice used for survival study. Some of the mice survived at the end of 28 days were also used for echocardiographic, hemodynamic and infarct size studies as indicated in each study. The rest of 232 mice survived from all kinds of 265 procedures (33 mice died) were used for 24h infarct size measurement (32 mice), Masson's trichrome stain (18 mice), arrhythmia analysis (28 mice), myeloperoxidase (MPO, 81) and TNFα (73) assays. In I/R model, mice were subjected to 30 min of myocardial ischemia followed by 24 hrs of reperfusion. Mice were divided into four groups also: new method of I/R (I/R-N, n=41) or sham (SI/R-N, n=16), classical method of I/R or sham I/R (I/R-C, n=40, SI/R-C, n=16, respectively). All animals were monitored after the surgery and received one dose (0.3mg/kg) of buprenophine within 6 hours post surgery and another dose was administered the following morning. No further analgesia was given thereafter.
Gao E., Lei Y.H., Shang X., Huang Z.M., Zuo L., Boucher M., Fan Q., Chuprun J.K., Ma X.L, & Koch W.J. (2010). A Novel and Efficient Model of Coronary Artery Ligation and Myocardial Infarction in the Mouse. Circulation research, 107(12), 1445-1453.
Publication 2010
Animals Animals, Laboratory Artery, Coronary Biological Assay Buprenorphine Cardiac Arrhythmia Echocardiography Hemodynamics Infarction Ligation Males Management, Pain Mice, House Myocardial Ischemia Operative Surgical Procedures Peroxidase Reperfusion trichrome stain Tumor Necrosis Factor-alpha
2
Exercise Training in Heart Failure
A complete description of the design of HF-ACTION has been published previously.15 (link) Briefly, HF-ACTION was a multicenter, randomized controlled trial of exercise training vs usual care in patients with left ventricular ejection fraction ≤ 35% and New York Heart Association (NYHA) class II to IV symptoms despite optimal heart failure therapy for at least 6 weeks. Patients were randomized from April 2003 through February 2007 within the United States, Canada, and France. Exclusion criteria included major comorbidities or limitations that could interfere with exercise training, recent (within 6 weeks) or planned (within 6 months) major cardiovascular events or procedures, performance of regular exercise training, or use of devices that limited the ability to achieve target heart rates. The protocol was reviewed and approved by the appropriate institutional review board or ethics committee for each participating center and by the coordinating center institutional review board. All patients provided written voluntary informed consent.
All patients were to undergo baseline cardiopulmonary exercise testing. Test results were reviewed by investigators to identify significant arrhythmias or ischemia that would prevent safe exercise training, to determine appropriate levels of exercise training, and to establish training heart rate ranges. Eligible patients were randomized 1:1 using a permuted block randomization scheme, stratified by clinical center and heart failure etiology (ischemic vs nonischemic). At the baseline clinic visit prior to randomization, demographics, socioeconomic status, past medical history, current medications, physical exam, and the most recent laboratory tests were obtained. Participants reported race and ethnicity at the time of study enrollment using categories defined by the National Institutes of Health. In an analysis to examine the effect of exercise training by subgroup, we used the reported race categories “black or African American” and “white” and combined all others as “other.” All cardiopulmonary exercise tests were sent to the HF-ACTION cardiopulmonary exercise core lab for review.
O’Connor C.M., Whellan D.J., Lee K.L., Keteyian S.J., Cooper L.S., Ellis S.J., Leifer E.S., Kraus W.E., Kitzman D.W., Blumenthal J.A., Rendall D.S., Miller N.H., Fleg J.L., Schulman K.A., McKelvie R.S., Zannad F, & Piña I.L. (2009). Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure: HF-ACTION Randomized Controlled Trial. JAMA : the journal of the American Medical Association, 301(14), 1439-1450.
Publication 2009
African American Cardiac Arrhythmia Cardiopulmonary Exercise Test Cardiovascular System Clinic Visits Congestive Heart Failure Ethics Committees Ethics Committees, Research Ethnicity Heart Ischemia Medical Devices Patients Pharmaceutical Preparations Physical Examination Rate, Heart Therapeutics Ventricular Ejection Fraction
3
Expanding PheWAS Phenotype Categorization
In this study, we revised and expanded our earlier PheWAS phenotype categorization to a total of 1,645 phenotypes identified from International Classification of Disease, Ninth revision, Clinical Modification (ICD9) codes. (Our initial PheWAS phenotype categorization included 744 phenotypes9 (link).) The ICD9 coding system is divided into four components: diseases, signs and symptoms (“three digit” codes, 001–999), external causes of injury (“E” codes), procedures (“two digit” codes 00.0–99.9) and supplemental classifications (“V” codes). The prior PheWAS code groupings included only diseases, signs and symptoms (three digit) ICD9 codes9 (link). We revised and expanded the PheWAS phenotypes by (i) adding V codes (commonly used to record personal histories of given diseases) and E codes (which refer to external causes of injury) to the PheWAS code mapping, (ii) redesigning the code system to be hierarchical, such that one phenotype could be a parent of another subphenotype (e.g., cardiac arrhythmias is a parent of atrial fibrillation, atrial flutter and other arrhythmias), and (iii) including more granular phenotypes into the coding system (e.g., “type 1 diabetes with ketoacidosis”). Creation of hierarchical phenotypes included creation of phenotypes not present in the ICD9 billing hierarchy, such as “inflammatory bowel disease” as the parent phenotype for “Crohn’s disease” and “ulcerative colitis.” In this process, we were guided by the hierarchical organization of the Clinical Classifications Software (CCS) produced by the Agency for Healthcare Research and Quality42 (link); the 2011 version of the CCS contains 727 phenotypes. The resulting PheWAS code group currently contains 1,645 phenotypes, 1,358 of which had at least 25 cases (a prevalence of 0.18% in our data set) in the eMERGE cohort, our threshold for these analyses. The current version of the PheWAS codes, with ICD9 mappings and control groups, is available from http://knowledgemap.mc.vanderbilt.edu/research/content/phewas.
Denny J.C., Bastarache L., Ritchie M.D., Carroll R.J., Zink R., Mosley J.D., Field J.R., Pulley J.M., Ramirez A.H., Bowton E., Basford M.A., Carrell D.S., Peissig P.L., Kho A.N., Pacheco J.A., Rasmussen L.V., Crosslin D.R., Crane P.K., Pathak J., Bielinski S.J., Pendergrass S.A., Xu H., Hindorff L.A., Li R., Manolio T.A., Chute C.G., Chisholm R.L., Larson E.B., Jarvik G.P., Brilliant M.H., McCarty C.A., Kullo I.J., Haines J.L., Crawford D.C., Masys D.R, & Roden D.M. (2013). Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nature biotechnology, 31(12), 1102-1110.
Publication 2013
Atrial Fibrillation Atrial Flutter Cardiac Arrhythmia Crohn Disease Diabetic Ketoacidosis Fingers Inflammatory Bowel Diseases Injuries Parent Phenotype Ulcerative Colitis
4
Nicotine Patch vs. Varenicline for Smoking Cessation

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
Addictive Behavior Alcoholic Beverages Angina Pectoris Arm, Upper Buffaloes Cardiac Arrhythmia Central Nervous System Stimulants Cerebrovascular Accident Coagulants Cocaine Contraceptives, Oral CYP2A6 protein, human Epistropheus Grafts High Blood Pressures Inhaler Kidney Liver Diseases Major Depressive Disorder Malignant Neoplasms Mental Disorders Mental Health Methamphetamine Monoamine Oxidase Inhibitors Monoxide, Carbon Myocardial Infarction Nicotine Nicotine Transdermal Patch Opiate Alkaloids Pharmaceutical Preparations Placebos Pregnancy Safety Substance Abuse Tobacco Use Disorder Tricyclic Antidepressive Agents Varenicline
5
Cardiovascular Evaluation in Outpatients
The study participants were symptomatic outpatients without diagnosed CAD whose physicians believed that nonurgent, noninvasive cardiovascular testing was necessary for the evaluation of suspected CAD. Additional inclusion criteria were an age of more than 54 years (in men) or more than 64 years (in women) or an age of 45 to 54 years (in men) or 50 to 64 years (in women) with at least one cardiac risk factor (diabetes, peripheral arterial disease, cerebrovascular disease, current or past tobacco use, hypertension, or dyslipidemia). Exclusion criteria were an unstable hemodynamic status or arrhythmias that required urgent evaluation for suspected acute coronary syndrome, a history of CAD or evaluation for CAD within the previous 12 months, or clinically significant congenital, valvular, or cardiomyopathic heart disease, or any reason that the patient could not be randomly assigned to either group safely (Table S1 in the Supplementary Appendix, available at NEJM.org).
Douglas P.S., Hoffmann U., Patel M.R., Mark D.B., Al-Khalidi H.R., Cavanaugh B., Cole J., Dolor R.J., Fordyce C.B., Huang M., Khan M.A., Kosinski A.S., Krucoff M.W., Malhotra V., Picard M.H., Udelson J.E., Velazquez E.J., Yow E., Cooper L.S, & Lee K.L. (2015). Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease. The New England journal of medicine, 372(14), 1291-1300.
Publication 2015
Acute Coronary Syndrome Cardiac Arrhythmia Cardiomyopathies Cardiovascular System Cerebrovascular Disorders Diabetes Mellitus Dyslipidemias Heart Heart Diseases Hemodynamics High Blood Pressures Outpatients Patients Peripheral Vascular Diseases Physicians Woman

Most recents protocols related to «Cardiac Arrhythmia»

1
Postoperative Cardiac Risk Assessment
The outcome was a composite of all-cause mortality or major cardiac events within 30 days of the index surgical procedure, which included acute myocardial infarction (AMI) and non-fatal ventricular arrhythmias identified using validated algorithms (Supplementary Table 2). This composite outcome is similar to other postoperative risk tools and was informed by perioperative cardiac risk assessment guidelines [11 (link)].
Harrison T.G., Hemmelgarn B.R., James M.T., Sawhney S., Manns B.J., Tonelli M., Ruzycki S.M., Zarnke K.B., Wilson T.A., McCaughey D, & Ronksley P.E. (2023). Prediction of major postoperative events after non-cardiac surgery for people with kidney failure: derivation and internal validation of risk models. BMC Nephrology, 24, 49.
Full text: Click here
Publication 2023
Cardiac Arrhythmia Health Risk Assessment Heart Heart Ventricle Myocardial Infarction Surgical Procedure, Cardiac
2
Pharmacomechanical Thrombus Fragmentation Protocol
Following popliteal access (required with the use of ultrasound guidance) or femoral access with a 10-F sheath under local anaesthesia and strict sterile techniques, RT using a ZelanteDVT catheter or a Solent catheter was performed for pharmacomechanical thrombus fragmentation, suction or aspiration. First, the RT catheter was slowly advanced through the thrombotic segment (only submerged in vessel diameter estimated > 6 mm). For patients without contraindications of thrombolysis, 3 mg of rt-PA [total injected volume of 50 ml] was intraclot injected under the Power Pulse® model. After 20 minutes of dwell time, with the pump unit active during slow catheter passages (3 mm/s to 5 mm/s), runs were performed across the thrombotic segment in a distal-to-proximal or adverse direction under fluoroscopic guidance. Each device activation run lasted at less than 20 seconds with breaks of 30 seconds between the runs to avoid arrhythmia, and the total run times were monitored and kept no more than 240 seconds.
Gong M., Fu G., Liu Z., Zhou Y., Kong J., Zhao B., Lou W., Gu J, & He X. (2023). Rheolytic thrombectomy using an AngioJet ZelanteDVT catheter or a Solent Omni catheter for patients with proximal vein thrombosis. Thrombosis Journal, 21, 25.
Full text: Click here
Publication 2023
Alteplase Blood Vessel Cardiac Arrhythmia Catheters Femur Fibrinolytic Agents Fluoroscopy Local Anesthesia Medical Devices Neoplasm Metastasis Patients Pulse Rate Sterility, Reproductive Suction Drainage Thrombus Ultrasonography
3
Evaluating AngioJet Thrombectomy Efficacy
Technical success was defined as the successful use of AngioJet RT. Thrombus score was calculated through venography imaging by two experienced interventional physicians independently depending on pre-RT, at the completion of RT or post-CDT, by adding the scores of six vein segments (common iliac vein, external iliac vein, common femoral vein, proximal and distal segments of femoral vein, and popliteal vein). Thrombus scores were 0 when the vein was patent and completely free of thrombus, 1 in condition of a partially occluded vein, and 2 in condition of a completely occluded vein (i.e., vein lumen completely occluded with massive thrombus). The score was calculated for each segment, resulting in possible total thrombus scores. The thrombus removal rate was calculated as follows: [total pre-RT scores - total completion of RT (or total post-CDT scores)]/total pre-RT scores × 100%. Thrombus removal grades were evaluated as grade III (100% thrombus removal rate with no residual clots), grade II (50–99% thrombus removal rate), and grade I (< 50% thrombus removal rate). Thrombus removal grades II and III (i.e., ≥50% thrombus removal rate) were considered clinical success [10 (link)], which consisted of primary RT success and adjunctive CDT success. The primary RT (defined as patients who did not require adjunctive CDT treatment) success was classified based on preprocedural and at completion of RT thrombus scores evaluated as grade II and grade III. Adjunctive CDT (defined as patients who required adjunctive CDT treatment) success was classified based on preprocedural thrombus scores and those at the end of adjunctive CDT that were evaluated as grade II and grade III. The requirement of necessary adjunctive PTA and/or stent placement to treat coexisting stenosis to obtain sufficient flow within the same hospital stay was recorded but not considered clinical failure.
The safety outcomes consisted of procedure-related and CDT-related complications. The former included vessel perforation or damage (such as extravasation or retention of contrast agent in the vessel wall), bradycardia, arrhythmias or acute kidney injury (AKI). With adherence to the Society of Interventional Radiology (SIR) [11 (link)], the latter feature was divided into major CDT-related complications, which were defined as intracranial bleeding or bleeding severe enough to result in death, surgery, cessation of therapy, or blood transfusion, and minor complications, which were defined as less severe bleeding manageable with local compression, sheath upsizing, and/or alterations of thrombolytic agent dose and anticoagulant dose [11 (link)]. The SIR classification of complications is listed in the Supplementary Table.
Gong M., Fu G., Liu Z., Zhou Y., Kong J., Zhao B., Lou W., Gu J, & He X. (2023). Rheolytic thrombectomy using an AngioJet ZelanteDVT catheter or a Solent Omni catheter for patients with proximal vein thrombosis. Thrombosis Journal, 21, 25.
Full text: Click here
Publication 2023
Anticoagulants Blood Transfusion Blood Vessel Cardiac Arrhythmia Clotrimazole Contrast Media Fibrinolytic Agents Iliac Vein Kidney Failure, Acute Operative Surgical Procedures Patients Phlebography Physicians Retention (Psychology) Safety Stenosis Stents Therapeutics Thrombus Vein, Femoral Veins Veins, Popliteal
4
Genetic Associations and Survival in AMD
SNP genotypes were denoted as 0/0 for homozygous reference alleles, 0/1 for heterozygous alleles, and 1/1 for homozygous alternate alleles (0: reference allele; 1: alternate allele). Association analysis of logistic regression was performed using the Python package statsmodels (Seabold et al., 2010 ). An additive model was used for the association between the SNPs and AMD. For additive logistic regression analysis, homozygous reference alleles, heterozygous alleles, and homozygous alternate alleles were respectively defined as the values 0, 1, and 2. The clinical data mining and management of the SQL server in TCVGH was conducted using Microsoft Azure Data Studio. Patient comorbidities included hypertension (ICD-9-CM codes 401.xx—405.xx), coronary artery disease (410.xx—414.xx), cardiac dysrhythmias (427.xx, 785.0, and 785.1), cerebrovascular diseases (433.xx—438.xx), chronic respiratory diseases (490—496), and hyperlipidemia (272.x). Individuals with any comorbidity were identified through diagnoses performed during at least two ambulatory visits to TCVGH. Statistical significance was defined as a p-value < 0.05.
Survival analysis was assessed by the Kaplan–Meier estimate using the R package survival (Therneau and Grambsch, 2000 ). Observation time was defined as the period of duration from the first outpatient visit for a comorbidity to the first time receiving a diagnosis for AMD. The survival curve was plotted by the R package survminer (https://CRAN.R-project.org/package=survminer). Log-rank tests for significant differences in survival time between the two groups were performed using the survdiff function in the survival package. A Cox proportional hazard (PH) model was used to estimate the hazard ratio (HR) using the coxph function in the survival package. For Cox PH model, homozygous reference alleles (0/0), heterozygous alleles (0/1), and homozygous alternate alleles (1/1) were respectively defined as the values 0, 1, and 2.
Shih C.H., Chuang H.K., Hsiao T.H., Yang Y.P., Gao C.E., Chiou S.H., Hsu C.C, & Hwang D.K. (2023). Genome-wide association study and identification of systemic comorbidities in development of age-related macular degeneration in a hospital-based cohort of Han Chinese. Frontiers in Genetics, 14, 1064659.
Full text: Click here
Publication 2023
Alleles Azure A Cardiac Arrhythmia Cerebrovascular Disorders Coronary Artery Disease Diagnosis Disease, Chronic Genotype Heterozygote High Blood Pressures Homozygote Hyperlipidemia Outpatients Patients Python Respiration Disorders Respiratory Rate Single Nucleotide Polymorphism
5
High-Flow Nasal Oxygen Therapy for COVID-19-Induced Acute Respiratory Failure
This retrospective and cross-sectional study was conducted in Trakya University Hospital Respiratory Intensive Care Units which was approved by the Trakya University Clinical Research Ethics Committee (TÜTF-BAEK 2021/275) and the Turkish Ministry of Health (2021-06-07T10_06_44). Patients diagnosed with ARF due to lung involvement of laboratory-confirmed (RT-PCR) COVID-19 and managed with HFNC at ICU admission were included in the study between April 2020 and January 2022.
As per the Turkish Ministry of Health COVID-19 management guideline,21 HFNC is indicated for patients with persistent hypoxemia or respiratory distress symptoms under low flow oxygen therapy systems. HFNC was administered in the ICU with HI-Flow StarTM (Dragerwerk AG & Co., Germany), which is set to deliver a flow rate up to 50 l/min with FiO2 to keep the patient’s SpO2 above 90%.
If deterioration in the patient’s level of consciousness, worsening dyspnea, malign arrhythmia, or hemodynamic instability were detected or more than 60% FiO2 under 50 l/min flow rate was required to keep the patient’s PaO2/FiO2 over 150 mmHg, it was considered a treatment failure. Non-invasive ventilation (NIV) or IMV was initiated as rescue therapy.
Data were abstracted from the hospital records and nurse charts. Patients’ demographics, body mass indices, comorbidities, Charlson Comorbidity Indices,22 (link) disease severity scores [Acute Physiology and Chronic Health Assessment (APACHE),23 (link) Sequential Organ Failure Assessment (SOFA)24 (link)] and laboratory findings (hemogram, d-dimer, ferritin, C-reactive protein, procalcitonin, arterial blood gas parameters within 2 hours thereafter HFNC initiation) at ICU admission; ROX indices at initiation, 2nd, 8th, 12th, 24th and 48th hours of HFNC; and out-comes (ICU and hospital length of stay, in 28-day mortality) were recorded (Figure 2). ROX index was calculated using the formula (SpO2/FiO2)/respiratory rate.18 (link) Patients were excluded who were younger than 18 years old and HFNC failed within 2 hours of the therapy.
Hancı P., Uysal A., Yüksel B, & İnal V. (2023). Rox Index Dynamics According to High Flow Nasal Cannula Success in Intensive Care Unit Patients with COVID-19-Related Acute Respiratory Failure. Balkan Medical Journal, 40(2), 111-116.
Publication 2023
Arteries Blood Cardiac Arrhythmia Consciousness COVID 19 C Reactive Protein Dyspnea Ethics Committees, Research Ferritin fibrin fragment D Hemodynamics Index, Body Mass Lung Noninvasive Ventilation Nurses Patients physiology Procalcitonin Respiratory Rate Respiratory System Reverse Transcriptase Polymerase Chain Reaction Saturation of Peripheral Oxygen Therapeutics Therapies, Oxygen Inhalation Youth

Top products related to «Cardiac Arrhythmia»

1
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
2
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
3
Prism 8 by GraphPad
Sourced in United States, Austria, Canada, Belgium, United Kingdom, Germany, China, Japan, Poland, Israel, Switzerland, New Zealand, Australia, Spain, Sweden
Prism 8 is a data analysis and graphing software developed by GraphPad. It is designed for researchers to visualize, analyze, and present scientific data.
4
Carto 3 by Johnson & Johnson
Sourced in United States, Sao Tome and Principe
CARTO 3 is a medical device designed for advanced cardiac mapping and visualization. It provides healthcare professionals with a platform to generate and analyze detailed 3D maps of the heart's electrical activity.
5
Powerlab by ADInstruments
Sourced in Australia, United States, United Kingdom, New Zealand, Germany, Japan, Spain, Italy, China
PowerLab is a data acquisition system designed for recording and analyzing physiological signals. It provides a platform for connecting various sensors and transducers to a computer, allowing researchers and clinicians to capture and analyze biological data.
6
Powerlab system by ADInstruments
Sourced in Australia, United States, United Kingdom, New Zealand, Germany, Japan, Canada
The PowerLab system is a versatile data acquisition hardware platform designed for laboratory research and teaching applications. It offers a range of input channels and signal conditioning options to accommodate a variety of experimental setups. The PowerLab system is capable of recording and analyzing various physiological signals, enabling researchers to capture and study relevant data for their studies.
7
Thermocool smarttouch by Johnson & Johnson
Sourced in United States
The Thermocool SmartTouch is a medical device used for diagnostic and treatment procedures. It provides precise temperature monitoring and control functionality to medical professionals.
8
Sas software version 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, Brazil, United Kingdom, Cameroon
SAS software version 9.4 is a comprehensive data analysis and management solution. It provides advanced statistical and analytical capabilities for organizations to manage, analyze, and report on their data. The software includes a range of tools and features to support various data-driven tasks, such as data manipulation, statistical modeling, and predictive analytics.
9
Reveal linq by Medtronic
Sourced in United States
The Reveal LINQ is a cardiac monitoring device designed to detect and record heart rhythm abnormalities. It is an insertable cardiac monitor that is placed under the skin during a minor surgical procedure.

More about "Cardiac Arrhythmia"

Cardiac arrhythmia, irregular heart rhythm, abnormal electrical activity, atrial fibrillation, ventricular tachycardia, bradycardia, SAS 9.4, Prism 8, CARTO 3, PowerLab, PowerLab system, Thermocool SmartTouch, Reveal LINQ, cardiovascular health, heart failure, sudden cardiac death, reproducibility, accuracy, PubCompare.ai, research optimization, protocols, literature, preprints, patents, AI-driven comparisons, cardiovascular medicine.
Cardiac arrhythmias are a diverse group of conditions characterized by irregularities in the heart's electrical signaling, leading to abnormal heart rhythms.
These can manifest in various forms, such as atrial fibrillation, ventricular tachycardia, and bradycardia, among others.
Untreated, cardiac arrhythmias can have serious consequences, including reduced blood flow, heart failure, and even sudden cardiac death.
Effectively managing and understanding cardiac arrhythmias is crucial for maintaining cardiovascular health.
PubCompare.ai is a powerful tool that can optimize cardiac arrhythmia research by enabling users to easily locate relevant protocols from literature, preprints, and patents, while leveraging AI-driven comparisons to identify the best protocols and products.
This innovative tool enhances reproducibility and accuracy in cardiac arrhythmia studies, allowing researchers to experience the future of research today and advance the field of cardiovascular medicine.
Whether you're using SAS 9.4, Prism 8, CARTO 3, PowerLab, Thermocool SmartTouch, or Reveal LINQ, PubCompare.ai can help you streamline your cardiac arrhythmia research and unlock new insights to improve patient outcomes.